遗传上升的脂蛋白 (a) 和心肌梗塞风险增加
Pia R Kamstrup1, Anne Tybjaerg-Hansen, Rolf Steffensen
1Department of Clinical Biochemistry, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
JAMA
|June 11, 2009
概括
高脂蛋白水平显著增加心肌梗塞 (MI) 风险. 遗传分析支持高脂蛋白和心脏病发作风险之间的因果关系,加强其在心血管疾病中的作用.
科学领域:
- 心血管遗传学 心血管遗传学
- 脂质代谢 脂质代谢是什么
- 流行病学 流行病学
背景情况:
- 脂蛋白水平升高是已知的心肌梗塞 (MI) 风险因素之一.
- 脂蛋白和心脏病发作风险之间的因果关系需要使用遗传数据进行进一步的研究.
研究的目的:
- 确定遗传数据是否支持高脂蛋白 (a) 水平与心肌梗塞 (MI) 风险之间的因果关系.
- 利用与脂蛋白水平相关的遗传变异作为因果推断的工具变量.
主要方法:
- 分析了三项丹麦人口研究 (CCHS,CGPS,CIHDS),包括超过4万名参与者.
- 测量血脂蛋白 (a) 水平和脂蛋白 (a) 环形IV型2 (KIV-2) 大小多态基因型.
- 利用多变量调整的考克斯回归和仪器变量分析来评估遗传决定性脂蛋白和心脏病风险之间的关联.
主要成果:
- 在哥本哈根城市心脏研究中,更高的血脂蛋白水平与心脏病发作风险比率的增加显著相关 (趋势P<.001).
- 这种KIV-2重复多态性解释了血脂蛋白水平变化的很大一部分.
- 仪器变量分析表明了因果关系,每次脂蛋白水平翻一番的危险比为1.22 (95% CI,1.09至1.37),相比之下,Cox回归的1.08 (95% CI,1.03-1.12).
结论:
- 这项研究提供了基因证据,支持高脂蛋白水平和心肌梗塞风险增加之间的因果关系.
- 这些发现强化了脂蛋白的作用,作为心血管疾病的显著,受遗传影响的危险因素.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:24Overview of Lipid Metabolism
7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
01:30Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747